Artal Group S.A. Bio N Tech Se Transaction History

Artal Group S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$113.32 - $241.49 $102 Million - $217 Million	-900,000 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$85.73 - $119.5 $8.57 Million - $12 Million	-100,000 Reduced 10.0%	900,000 $98.3 Million
Q4 2020 Feb 11, 2021	SELL	$72.71 - $129.54 $53.2 Million - $94.7 Million	-731,214 Reduced 42.24%	1,000,000 $81.5 Million
Q3 2020 Nov 13, 2020	SELL	$57.81 - $104.17 $15.5 Million - $28 Million	-268,786 Reduced 13.44%	1,731,214 $120 Million
Q2 2020 Aug 14, 2020	SELL	$38.58 - $66.74 $8.8 Million - $15.2 Million	-228,130 Reduced 10.24%	2,000,000 $133 Million
Q1 2020 May 14, 2020	SELL	$28.55 - $92.0 $11.4 Million - $36.8 Million	-400,000 Reduced 15.22%	2,228,130 $130 Million
Q4 2019 Feb 13, 2020	BUY	$12.75 - $36.91 $33.5 Million - $97 Million	2,628,130 New	2,628,130 $89 Million

328

40.6M

845K

1.23M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $28.8B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.